HK1040625B - 用於改善替普拉那维的药物动力学的方法 - Google Patents

用於改善替普拉那维的药物动力学的方法 Download PDF

Info

Publication number
HK1040625B
HK1040625B HK02102194.8A HK02102194A HK1040625B HK 1040625 B HK1040625 B HK 1040625B HK 02102194 A HK02102194 A HK 02102194A HK 1040625 B HK1040625 B HK 1040625B
Authority
HK
Hong Kong
Prior art keywords
tipranavir
ritonavir
bid
administration
effective amount
Prior art date
Application number
HK02102194.8A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040625A1 (en
Inventor
J‧J‧菲瑞
J‧R‧鲍德温
M‧T‧柏林
J‧R‧鮑德溫
Original Assignee
法玛西雅厄普约翰美国公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法玛西雅厄普约翰美国公司 filed Critical 法玛西雅厄普约翰美国公司
Publication of HK1040625A1 publication Critical patent/HK1040625A1/xx
Publication of HK1040625B publication Critical patent/HK1040625B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02102194.8A 1998-11-04 1999-10-29 用於改善替普拉那维的药物动力学的方法 HK1040625B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
US60/106,963 1998-11-04
PCT/US1999/021469 WO2000025784A1 (en) 1998-11-04 1999-10-29 Method for improving the pharmacokinetics of tipranavir

Publications (2)

Publication Number Publication Date
HK1040625A1 HK1040625A1 (en) 2002-06-21
HK1040625B true HK1040625B (zh) 2005-04-01

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102194.8A HK1040625B (zh) 1998-11-04 1999-10-29 用於改善替普拉那维的药物动力学的方法

Country Status (13)

Country Link
US (1) US6147095A (https=)
EP (1) EP1126847A1 (https=)
JP (1) JP2002528502A (https=)
CN (1) CN1154491C (https=)
AU (1) AU762349B2 (https=)
BR (1) BR9914940A (https=)
CA (1) CA2346131C (https=)
CO (1) CO5160321A1 (https=)
HK (1) HK1040625B (https=)
MY (1) MY118526A (https=)
PE (1) PE20001296A1 (https=)
TW (1) TW580387B (https=)
WO (1) WO2000025784A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
DE60132103T2 (de) * 2000-10-31 2008-04-17 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
AU2003295940A1 (en) * 2002-12-16 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
WO2004054586A1 (en) * 2002-12-16 2004-07-01 Boehringer Ingelheim International Gmbh Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
EP1610781A1 (en) * 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
WO2006052373A2 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
WO2006055660A2 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006055754A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and reverset
CA2585663A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
US20060142344A1 (en) * 2004-12-01 2006-06-29 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW695634
EP1819333A1 (en) * 2004-12-01 2007-08-22 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gw873140
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
MA34215B1 (fr) * 2010-04-02 2013-05-02 Phivco 1 Llc Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique
AU2012262322B2 (en) * 2011-05-30 2016-11-03 Autotelic Llc Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
TW580387B (en) 2004-03-21
AU1440400A (en) 2000-05-22
CA2346131C (en) 2013-01-15
CA2346131A1 (en) 2000-05-11
HK1040625A1 (en) 2002-06-21
PE20001296A1 (es) 2000-11-23
BR9914940A (pt) 2001-07-10
MY118526A (en) 2004-11-30
US6147095A (en) 2000-11-14
CN1324237A (zh) 2001-11-28
CO5160321A1 (es) 2002-05-30
CN1154491C (zh) 2004-06-23
WO2000025784A1 (en) 2000-05-11
AU762349B2 (en) 2003-06-26
EP1126847A1 (en) 2001-08-29
JP2002528502A (ja) 2002-09-03

Similar Documents

Publication Publication Date Title
CN1154491C (zh) 用于改善替普拉那维的药物动力学的方法
CN1290500C (zh) 逆转录病毒蛋白酶抑制剂的联合
Molla et al. Recent developments in HIV protease inhibitor therapy
Lamarre et al. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease
CN1301158A (zh) 用于治疗人类获得性免疫缺陷病毒和其它病毒感染的组合物
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
US20110003764A1 (en) Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors
CN1684683A (zh) Hcv丝氨酸蛋白酶的有效抑制剂
EP3033084A1 (en) Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
US5977086A (en) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
WO2015120057A1 (en) Pharmaceutical combinations against co-infection with hiv and tuberculosis
Lambert et al. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection
WO2011089166A1 (en) Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
Kubin et al. Antiretroviral agents
Fujiwara et al. Thiadiazole Derivatives: Highly Potent and Selective Inhibitors of Human Immunodeficiency Virus Type 1 (HIV‐1) Replications In Vitro
CN1537855A (zh) 炭球菌素及其制备方法和应用
EP1712231A2 (en) Method for improving the pharmacokinetics of tipranavir
CN1768733A (zh) 芳香硝基化合物在制备治疗艾滋病药物中的应用
Threlkeld et al. Antiretroviral therapy
Rawlins et al. Saquinavir
CN1901914A (zh) 利用氯喹和蛋白酶抑制剂的组合物治疗hiv或疟疾的方法
CN1180314A (zh) 血管紧张素转化酶抑制剂和降低副作用量的醛固酮拮抗剂的组合物
CN1180313A (zh) 血管紧张素转化酶抑制剂、降低副作用量的醛固酮拮抗剂和利尿剂的组合物
CN1600330A (zh) 五味子及其提取物治疗肿瘤多药耐药的用途
HK1085921A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20191028